Daily honey consumption's effect on insulin resistance in obese women
The Influence of Daily Honey Consumption on Insulin Resistance in Obese Women with Insulin Resistance
This study is testing whether eating honey every day can help reduce insulin resistance in obese women aged 19-45 and possibly lower their risk of diabetes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 19 Years to 45 Years |
| Sex | Female |
| Sponsor | University of Jordan Academic / other |
| Locations | 2 sites (Amman, Amman, Jordan and 1 other locations) |
| Trial ID | NCT05427799 on ClinicalTrials.gov |
What this trial studies
This study evaluates the impact of daily honey consumption on insulin resistance (IR) in obese women aged 19-45. It aims to determine whether honey, known for its bioactive properties, can serve as a preventive measure against diabetes by improving IR and inflammatory markers. Sixty participants will be randomly assigned to either a honey group or a jell-O group, consuming a daily dose for six months. The study will assess changes in IR, inflammatory biomarkers, and body fatness to understand honey's potential antidiabetic effects.
Who should consider this trial
Good fit: Ideal candidates are premenopausal obese women aged 19-45 with insulin resistance.
Not a fit: Patients with diabetes, significant weight changes, or those on medications affecting glucose or lipid levels may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a natural dietary intervention to improve insulin resistance and reduce diabetes risk in obese women.
How similar studies have performed: While the effects of honey on health have been noted, this specific approach to improving insulin resistance in obese women is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Female * 19-45 years * Obese (BMI \>= 30 kg/m\^2) * Premenopausal Exclusion Criteria: * Individual who use any drug or supplements known to affect lipid, glucose for at least the last three months. * Individual who previous insulin treatment * Smokers * Individual who have diabetes, kidney, liver, or hormonal diseases * Individual who have significant weight changes \> 5% during the past 6 months * Women who are postmenopausal
Where this trial is running
Amman, Amman, Jordan and 1 other locations
- Jordan University Hospital — Amman, Amman, Jordan, Jordan (Recruiting)
- The University of Jordan — Amman, Amman, Jordan, Jordan (Not_yet_recruiting)
Study contacts
- Principal investigator: Shatha S Hammad, PhD — The University of Jordan
- Study coordinator: Shatha S Hammad, PhD
- Email: sh.hammad@ju.edu.jo
- Phone: +96265355000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.